NVAX has received solid support in the buy zone ($6.50-$7) throughout Q3. I think NVAX will have its breakout in Q4 and the key resistance targets are the $16.21 and $23.13 price levels. October will be an important month for NVAX with the European Union deciding whether to approve the NVAX COVID vaccine. Germany already has an interest in placing an order for 10.6 million vaccine doses in Q4 if NVAX does receive approval.
Want more of my content?
Check out my YouTube and Twitter updates across all financial markets
Join my exclusive Discord community for swing trading, options trading, and long-term investing.
There is a free trial period for the group
Links👇
Check out my YouTube and Twitter updates across all financial markets
Join my exclusive Discord community for swing trading, options trading, and long-term investing.
There is a free trial period for the group
Links👇
